fda warning letters compounded semaglutide tirzepatide 2024 2025 Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

20.70

★★★★☆4.8 (126)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

20.40

★★★★★4.9 (98)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

27.40

★★★★★5.0 (157)

Compound versions of GLP-1 drugs for weight loss halted by FDA

28.12

★★★★★4.7 (84)

September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA – Partnership for Safe Medicines

27.58

★★★★★4.9 (203)

Fifth Circuit probes FDA ban on compounded GLP-1s

27.04

★★★★★5.0 (176)

The FDA has warned six online companies for selling compounded retatrutide, an unlicensed weight-loss drug that has gained traction among social media influencers., "All of a sudden, you have

29.00

★★★★★4.8 (132)